INTRODUCTION: An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. METHODS: Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline "self-quit" scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. RESULTS: The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5% at 4-week follow-up to 3.6% at 52 weeks. The group service achieved a higher quit rate (6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of £4,800 for the group support and £2,600 for pharmacy one-to-one counseling. CONCLUSIONS: Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.
INTRODUCTION: An observational study examining 1-year follow-up of clients of two National Health Service smoking cessation services in Glasgow was used to inform a cost-effectiveness analysis. One service involved 7 weeks of group-based support (n = 411) and the other consisted of up to 12 weeks of one-to-one counseling with pharmacists (n = 1,374). Pharmacological aids to quitting (e.g., nicotine replacement therapy) were available to all clients. METHODS: Quit rates were calculated for each service at 52 weeks after the quit date, and these were used for an economic evaluation of both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in comparison with a baseline "self-quit" scenario. The annual cost-effectiveness model established the incremental cost per 52-week quitter, while a Markov model was developed for the lifetime analysis to estimate the potential lifetime outcomes in terms of cost per quality-adjusted life years (QALY) gained, to account for the benefits quitters will receive in terms of extended life years and improvements in quality of life from smoking cessation. RESULTS: The proportion of carbon monoxide-validated quitters from both services combined fell from 22.5% at 4-week follow-up to 3.6% at 52 weeks. The group service achieved a higher quit rate (6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs. The lifetime analysis resulted in an incremental cost per QALY of £4,800 for the group support and £2,600 for pharmacy one-to-one counseling. CONCLUSIONS: Despite disappointing 1-year quit rates, both services were considered to be highly cost-effective.
Authors: Katy Ellis Hilts; Robin L Corelli; Alexander V Prokhorov; Susan M Zbikowski; Alan J Zillich; Karen Suchanek Hudmon Journal: Pharmacy (Basel) Date: 2022-05-30
Authors: Máirtín S McDermott; Heather Thomson; Robert West; Jennifer A M Kenyon; Andy McEwen Journal: BMC Health Serv Res Date: 2012-05-23 Impact factor: 2.655
Authors: David M Tappin; Linda Bauld; Carol Tannahill; Linda de Caestecker; Andrew Radley; Alex McConnachie; Kathleen Boyd; Andrew Briggs; Liz Grant; Alan Cameron; Susan Macaskill; Lesley Sinclair; Brenda Friel; Tim Coleman Journal: Trials Date: 2012-07-20 Impact factor: 2.279
Authors: Rosemary Hiscock; Susan Murray; Leonie S Brose; Andy McEwen; Jo Leonardi Bee; Fiona Dobbie; Linda Bauld Journal: Addict Behav Date: 2013-07-21 Impact factor: 3.913
Authors: Tamara J Brown; Adam Todd; Claire O'Malley; Helen J Moore; Andrew K Husband; Clare Bambra; Adetayo Kasim; Falko F Sniehotta; Liz Steed; Sarah Smith; Lucie Nield; Carolyn D Summerbell Journal: BMJ Open Date: 2016-02-29 Impact factor: 2.692
Authors: Fujian Song; Vivienne Maskrey; Annie Blyth; Tracey J Brown; Garry R Barton; Paul Aveyard; Caitlin Notley; Richard Holland; Max O Bachmann; Stephen Sutton; Thomas H Brandon Journal: Nicotine Tob Res Date: 2015-07-07 Impact factor: 4.244